Enhancing Current Chemotherapy by Making it More Effective and Safer
“It is the tension between creativity and skepticism that has produced the stunning and unexpected findings of science.”
– Carl Sagan
A new and promising potential treatment for cancer
In the past 50 years, over $100 billion has been spent on cancer research by the National Cancer Institute, with much more from private firms. Yet, cancer remains the second leading cause of death, with mortality rates unchanged. Immunotherapy, hailed as a breakthrough, treats only 8% of cancers and costs up to $1 million per patient, making it unviable even for those it could help.
Lahjavida has made progress in targeting lung, breast, and colon cancer cells with a drug that combines a tumor-targeting dye, unique linkers, and "Standard of Care" chemotherapy. This drug activates inside cancer cells, destroying them while being minimally toxic to healthy tissue. We are now in the process of raising $5.2 million funds to confirm and improve these results in animal models by 2024 and ultimately aim to raise $15 million for human trials by 2026 or 2027.
​
WHY LAHJAVIDA
​
Lahjavida, Inc. is a cancer research venture with a vision to improve and extend the gift of life for patients. Our patented technologies utilize the unique tumor-targeting capabilities of special fluorescing dyes, in conjunction with "standard-of-care" chemotherapy drugs. This treatment promises to enhance the effectiveness of the therapy, while preserving healthy tissues. The tumor-targeting dyes act as the delivery mechanism for the drugs, while ensuring that the drugs are "turned off" until the Lahjavida compounds reach the tumor site. Once there, our unique linker system "dissolves", releasing the drug and activating it. This technology allows for a more effective, less toxic, and a better way to deliver drugs exactly where they are needed, while protecting healthy tissues from the toxic impact of traditional chemotherapy. These dyes bind to over 30 different cancer types, holding tremendous promise for future treatments. Most importantly, this solution will potentially treat metastatic cancers, which pose the most serious dangers to patients. This is not a dream. Lahjavida has pre-clinical data supporting all of these claims. We are on the doorstep of a breakthrough in cancer treatment. Join us in improving and extending the gift of life for millions of future cancer patients.
SUMMARY
​
Lahjavida has shown significant progress in cancer treatment. We can precisely target lung, breast, and colon cancer cells using a drug design with a tumor-targeting dye, special linkers, and standard chemotherapy drugs. This drug activates inside cancer cells, destroying them while remaining minimally toxic to healthy tissue.
​
Our research demonstrates that standard chemotherapy drugs can be attached to tumor-targeting dyes via cleavable linkers. In animal models, this combination reliably targets tumors, with linkers designed to cleave only in the cancer cell environment. Data shows cancer cells begin to die within 8 days of injection.
STATUS
​
We are advancing towards our goal of confirming initial results in our cancer research initiative. Our primary objective for 2024 is to achieve significant progress in reducing or eliminating cancer in an animal model. This involves demonstrating that our compound can effectively accumulate in tumor tissues at sufficient doses, which is essential for treatment efficacy.
In addition, we are focused on validating our radiowave machine's capability to heat gold nanoparticles within the animal model, a critical step in our approach. To facilitate this important research, we are collaborating closely with UC Denver and UCCS, leveraging their expertise and resources.
Lahjavida is committed to creating and manufacturing the required compound, ensuring the integrity and reliability of our experimental efforts. We remain dedicated to progressing our research in line with our timeline, aiming to qualify for human trials by 2026 or 2027.